
As specialty drug complexity grows, agentic technology puts the right access, adherence, and affordability resources at the provider’s fingertips at prescribing.

As specialty drug complexity grows, agentic technology puts the right access, adherence, and affordability resources at the provider’s fingertips at prescribing.

The future is agent-first but human when it matters — AI handles repetitive tasks while humans manage exceptions, complexity, and regulatory needs.

Agentic AI turns wasted windshield time into productive CRM updates and deploys always-on virtual reps to support providers whenever information is needed.

Pharma field forces face three key challenges: scaling services beyond tier one, shifting from reactive to proactive engagement, and empowering teams with agentic AI.

Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.

With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.

AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.

AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.

Ignite Proteomics measures phosphorylation states to show which proteins are actively driving a tumor—guiding therapy beyond what IHC alone reveals.

When tumors shift, old treatments stop working. Dr. Brian Corgiat explains why real-time tumor profiling is critical to effective therapy.

Dr. Brian Corgiat makes the case for phosphoproteome testing—measuring what’s actively driving a tumor right now, not just static mutations.

Ignite Proteomics’ Dr. Brian Corgiat explains why tumors change over time—and why treatment must adapt to the current tumor, not the original.

Dr. Jay Lalezari of CytoDyn explains why Leronlimab’s circulating tumor DNA results in colorectal cancer represent a unique, mechanism-specific proof of concept rather than a broader template.

Dr. Jay Lalezari, CytoDyn’s CEO and CMO, discusses his path from HIV clinician to drug developer.

Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.

Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.

Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.

Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.

Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.

Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.

Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.

Shionogi’s Dr. Draica on why COVID-19 still matters — and why the window between exposure and symptoms is where XOCOVA can intervene.

Brox.AI’s Hamish Brocklebank on why it retired “digital twin” for “digital clone” — and why the distinction matters for pharma research accuracy.

Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.

Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.

Incubate’s John Stanford on why MFN deals are voluntary in name only — and why the leverage looks a lot like the IRA’s 95% excise tax.

Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.

Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is as important as supply chain resilience.

Fox Rothschild's Marc Wagner on how 503A pharmacies and 503B outsourcing facilities fill drug supply gaps — from COVID injectables to GLP-1s.

Fox Rothschild's Marc Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and FDA site approvals that take years.